Stay updated on Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedUpdated the page’s revision/version indicator from v3.5.2 to v3.5.3, reflecting a minor platform or display update rather than a substantive change to the study record.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision: v3.5.2 updated from v3.5.0.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check56 days agoChange DetectedPage revision updated to v3.4.3; previous revision v3.4.2 was removed.SummaryDifference0.0%

- Check77 days agoChange DetectedFallopian Tube Cancer is now listed among the study's conditions, expanding the scope of eligible diseases. This clarifies the target patient population and improves searchability and eligibility assessment.SummaryDifference0.0%

- Check84 days agoChange DetectedPrimary Peritoneal Carcinoma was added to the conditions list and the Genetic and Rare Diseases Information Center resource was added to Resources, with a v3.4.2 revision noted. The government funding status notice and prior revision notice (v3.4.1) were removed.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial page.